Clinical and Experimental Reproductive Medicine

  • 제32권2호
  • /
  • Pages.71-90
  • /
  • 2005
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지

GnRH Antagonist를 이용한 과배란유도

  • 김정훈 (울산의대 서울아산병원)
  • 발행 : 2005.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. 이방현, 김정훈, 오영미, 김성훈, 채희동, 강병문. 체외수정시술을 위한 과배란유도에 있어 GnRH antagonist 다회투여법과 GnRH agonist 장기요법의 비교연구. 대한산부학회지 2003;45(6):1202-8
  2. 최정원, 김정훈, 이향아, 홍석호, 나희영, 이영진, 등. 체외수정시술을 받는 다낭성난소증후군 환자들에서 GnRH agtaginist를 이용한 과배란 유도의 효용성. 대한산부학회지 2005; 48(3): 716-25
  3. 최정원, 김정훈, 이향아, 홍석호, 나희영, 이영진, 등. 성선자극호르몬 길항제를 이용하나 과배란유도에 있어 경구 피임제를 이용한 전처치가 체외수정시술의 결과에 미치는 영향. 대한산부학회지 2005;48(4):954-61
  4. 최정원, 김정훈, 이향아, 홍석호, 나희영, 이영진, 등. 저반응군 환자들에서 GnRH antagonist를 이용한 과배란유도시 경구 피임제 전처치의 효용성. 대한산부학회지 2005;48(4):987-95
  5. Albano C, Felberbaum RE, Smitw J, RiethmullerWinzen H, Engel J. Diedrich K, et al. Ovarian sitmulation with HMG: results of a prospective randomized phase III European study comparing the luteinzing hormone-releasing hormone (LHRH)antagonist cetrorelix and the LHRH-gonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000; 15: 526-31 https://doi.org/10.1093/humrep/15.3.526
  6. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001; 16(5): 868-70 https://doi.org/10.1093/humrep/16.5.868
  7. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002; 17: 874-85 https://doi.org/10.1093/humrep/17.4.874
  8. Bracero N, Jurema M, Vlahos N, Kolp L, Garcia J. Polycystic ovarian syndrome (PCOS) patients have a favorable response to ganirelix acetate during controlled ovarian hyperstimulation (COH) for in vitro fertilization(lVF)-embryo transfer (ET). Fertil Steril 2002; 78(suppI3): S149-50
  9. Cheung LP, Lam PM, Lok IH, Chiu TTY, Yeung SY, Tjer CC, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 2005; 20(3): 616-21 https://doi.org/10.1093/humrep/deh668
  10. Copperman AB. Antagonists in poor-responder patients. Fertil Steil 2003; 80(suppl 1): S16-24.
  11. Craft I, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols? Hum Reprod 1999; 14: 2959-62 https://doi.org/10.1093/humrep/14.12.2959
  12. Dadson WC, Hughes CL, Yancy SE, Haney AF. Clinical characteristics of ovulation induction with human menopausal gonadotropins with and without leuprolide acetate in polycystic ovary syndrome. Fertil Steril 1989; 52: 915-8
  13. Daya S. Gonodotrophin-releasing hormone agonists protocols for pituitary desensitization in vitro fertilization and gamete intrafallopisn transfer cycles. Cochrane Database Syst Rev 2000; 2: CD001299
  14. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, et al. Suppression of the endogenous luteinzing hormone surge by the gonadotrophinreleasing hormone antagonist cetrorelix during ovarian stimulation. Hum Reprod 1994; 9: 788 -91
  15. Elkind-Hirsch KE, Webster BW, Brown C, Vernon MW. Concurrent Antagon and Follistim therapy for ovulation induction in women with polycystic ovary syndrome (PeOS). Fertil Steril 2003; 79: 603-7 https://doi.org/10.1016/S0015-0282(02)04696-4
  16. European Orgalutran Study. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation wiht recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000; 15: 1490-8 https://doi.org/10.1093/humrep/15.7.1490
  17. European-Middle East OrgaIutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stumulation. Hum Reprod 2001; 16: 644-51 https://doi.org/10.1093/humrep/16.4.644
  18. Felberbaum RE, Reissmann T, Kupker W, Bauer 0, al-Hasani S, Diedrich C, et al. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonist (Cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod BioI 1995; 61: 151-5 https://doi.org/10.1016/0301-2115(95)02138-W
  19. Flemming R, Haxton MJ, Hamilton MP, MacCune GS, Black WP, MacNaughton MC, et al. Successful treatment of infertile women with oligomenorrhea using a combination of LHRH agonist and exogeneous gonadotrophins. Br J Obstet Gynaecol 1985; 92: 369-73 https://doi.org/10.1111/j.1471-0528.1985.tb01111.x
  20. Auker M, Grifo 1, Leader A, Levy M, Meldrum D, Muasher Sl, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75: 38-45 https://doi.org/10.1016/S0015-0282(00)01638-1
  21. Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multipledose protocol. Hum Reprod 2005; 20(5): 1200-6 https://doi.org/10.1093/humrep/deh741
  22. Hernandez ER. Embryo implantation and GnRH antagonists: embryo implatation: the Rubicon for GnRH antagonists. Hum Reprod 2000; 15: 1211-6 https://doi.org/10.1093/humrep/15.6.1211
  23. Homburg R, Levy T, Berkovitz D, Farchi J, Feldberg D, Ashkenazi J, et al. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovary syndrome. Ferril Steril 1993; 59: 527-31
  24. Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonodotrophin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta analysis of randomized controlled trials. Fertil Steril 1992; 58(5): 888-96
  25. Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod 2004; 19: 1993-2000 https://doi.org/10.1093/humrep/deh375
  26. Kim CH, Lee YJ, Hong SH, Nah HY, Kim SH, Chae HD, et al. Efficacy of GnRH antagonist during early and late controlled ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF-ET. Hum Reprod 2004; 19 (suppl 1): i104 https://doi.org/10.1093/humrep/deh036
  27. Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotrophin releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003; 79: 873-90 https://doi.org/10.1016/S0015-0282(02)04920-8
  28. Ludwig M, Katalinic A, Banz C, Schroder AK, Loning M, Weiss 1M, et a1. Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod 2002; 17(11): 2842-5 https://doi.org/10.1093/humrep/17.11.2842
  29. Mannaerts B, Gordon K. Embryo implantation and GnRH antagonists: GnRH antagonist do not activate the GnRH receptor. Hum Reprod 2001; 15: 1882-3 https://doi.org/10.1093/humrep/15.9.1882
  30. Nikolettos N, Al-Hasani S, Felberbaum R, Demirel LC, Kupker W, Montzka P, et al. Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Obstet Gynecol 2001; 97: 202-7
  31. Olivennes F, Fanchin R, Bouchard P, de Ziegler D, Taieb J, Selva J, et al. The single or dual administration of the gonadotrophin-releasing hormone antagonist Cetrorelix in an in vitro ferrilizationembryo transfer program. Fertil Steril 1994; 62: 468-76
  32. Olivennes F, Alvarez S, Bouchard P, Fanchin R, SalatBaroux J, Frydman R. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVFembryo transfer: s dose finding study of 3 versus 2 mg. Hum Reprod 1998; 13: 2411-4 https://doi.org/10.1093/humrep/13.9.2411
  33. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilizationembryo transfer with a single dose of a luteinizing hormone-releasing hormone (LHRH) antagonist (Cetrorelix) or a depot formula of an LHRH agonist (triptorelin). Fertil Steril 2000; 73: 314-20 https://doi.org/10.1016/S0015-0282(99)00524-5
  34. Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002; 8(3): 279-90 https://doi.org/10.1093/humupd/8.3.279
  35. Ortmann 0, Weiss JM, Diedrich K. Embryo implantation and GnRH antagonist: ovarian actions of GnRH antagonists. Hum Reprod 2001; 16: 608-11 https://doi.org/10.1093/humrep/16.4.608
  36. Rongieres-Bertrand C, Olivennes F, Righini C, Fanchin R, Taieb J, Hamamah S, et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 1999; 14: 683-8 https://doi.org/10.1093/humrep/14.3.683
  37. Schoolcraft WB, Gardner DK, Lane M, Schlenker T, Hamilton F, Meldrum DR. Blastocyst culture and transfer: analysis of results and parameters affecting outcome in two in vitro fertilization program. Fertil Steril 1999; 72: 604-9 https://doi.org/10.1016/S0015-0282(99)00311-8
  38. Shapiro DB. Introduction. Fertil Steril 2003; 80(suppl 1): S1-7.
  39. Tavaniotou A, Smitz J, Bourgain C, Devroey P. Ovulation induction disrupts luteal phase function. Ann N Y Acad Sci 2001; 943: 55-63. https://doi.org/10.1111/j.1749-6632.2001.tb03790.x